AUROBINDO

August 30, 2019

To Listing Department, **NATIONAL STOCK EXCHANGE OF INDIA LIMITED** Exchange Plaza, Bandra Kurla Complex, Bandra (E), **MUMBAI - 400 051** **Company Code No. AUROPHARMA**	To The Corporate Relations Department **BSE LIMITED** Phiroz Jeejeebhoy Towers, 25th floor, Dalal Street, **MUMBAI - 400 001** **Company Code No. 524804**

Dear Sir,

Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

We inform you that our wholly owned subsidiary, Helix Healthcare B.V, Netherlands, has on August 29, 2019 entered into an agreement with Shanghai LongJin Investment Company Ltd., China and Sveva Capitals, Hongkong to establish a Joint Venture Company in China under the name of 'Longxiang Pharma Taizhou Co Ltd'., for development, manufacturing, marketing and sale of pharmaceutical products for China excluding Taiwan, Hongkong and Macau.

The disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Part A of Schedule III of the aforesaid regulations, is attached as **'Annexure A'.**

Please take the information on record.

Thanking you,

Yours faithfully,
For AUROBINDO PHARMA LIMITED

B. Adi Reddy
Company Secretary

Enclosures: as above.

AUROBINDO

Annexure - A

Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

a) Name (s) of the parties with whom the agreement entered	Helix Healthcare B.V., Netherlands (Helix), a wholly owned subsidiary of the Company and Shanghai LongJin Investment Company Ltd., China (LongJin) and Sveva Capitals, Hongkong (Sveva) have entered into a Joint Venture Agreement to establish a Joint Venture Company (JVC) in China under the name of 'Longxiang Pharma Taizhou Co Ltd'., for development, manufacturing, marketing and sale of pharmaceutical products for China excluding Taiwan, Hong Kong and Macau.
b) Purpose of entering into agreement	To establish a Joint Venture Company in China for development, manufacturing, marketing, distribution and sale of pharmaceutical products
c) Shareholding, if any, in the entity with whom the agreement is executed.	Neither the Company nor Helix is having any shareholding in LongJin and Sveva. LongJin and Sveva are not having any shareholding in the Company / Helix. The percentage of shareholding in the JVC will be: Helix : 57% LongJin : 40% Sveva : 3%
d) Significant terms of the agreement (in brief) special rights like right to appoint directors, first right to share subscription in case of issuance of shares, right to restrict any change in capital structure etc.,	Helix has the right to appoint 3 directors and LongJin has the right to appoint 2 directors in JVC. Parties have rights to subscribe in proportion of their shareholding in case of any further issuances by JVC. If either Party intends to transfer all or part of its capital in the JVC to other than their affiliates, the other Party shall have the first right of refusal to buy such Shares. Commencement of commercial production of JVC is expected during 2022-23.
e) Whether, the said parties are related to promoter / promoter group / group companies in any manner. If yes, nature of relationship	LongJin and Sveva, the JV partners, are independent companies registered in China and Hong Kong. Helix is a wholly owned subsidiary of Aurobindo Pharma Limited. Other than the above, the parties are not related to the promoter/ promoter group/ group companies of Aurobindo Pharma Limited.

AUROBINDO PHARMA LTD.

f) Whether the transaction would fall within related party transactions? If yes, whether the same is done at 'arms length'.	No
g) In case of issuance of shares to the parties, details of issue price class of shares issued	The total equity will be USD 35 million and it will be funded in proportion to JV partners' shareholding in the JVC.
h) Any other disclosures related to such agreements, viz., details of nominees on the board of directors of the listed entity, potential conflict of interest arising out of such agreements, etc.,	Nil
i) In case of termination or amendment of agreement, additional details, if any.	All other terms including termination or amendment of JV agreement is subject to mutual consent.

AUROBINDO PHARMA LTD. HYD.